News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Opinion Editor's Corner AHA 2025 What’s Going to Be Hot at AHA 2025? Michael O'Riordan November 05, 2025
News Conference News AHA 2024 One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024 Shelley Wood November 14, 2024
News Conference News AHA 2023 Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina Michael O'Riordan November 11, 2023
News Conference News AHA 2023 MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia L.A. McKeown November 11, 2023
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Conference News AHA 2021 No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis Michael O'Riordan November 15, 2021
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Conference News AHA 2018 EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients Yael L. Maxwell November 16, 2018
News Conference News AHA 2018 Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI Michael O'Riordan November 14, 2018
News Conference News AHA 2018 TiCAB: Ticagrelor No Help for Preventing Graft Failure Post-CABG Shelley Wood November 13, 2018
News Conference News AHA 2018 Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis Caitlin E. Cox November 13, 2018
News Conference News AHA 2018 VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer Shelley Wood November 10, 2018
News Conference News AHA 2017 Methamphetamine Use Growing More Common in Veterans With Heart Failure Todd Neale November 24, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More Shelley Wood November 09, 2017
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016